CAS號(hào)	25322-68-3	產(chǎn)地	國(guó)產(chǎn)
規(guī)格	50ml	級(jí)別	化工級(jí)
證書	ISO系列證書

PEG300 (Synonyms: 聚乙二醇; Polyethylene glycol 300)

PEG300 (Polyethylene glycol 300)，分子量為300的中性聚合物，由乙二醇重復(fù)單元形成的水溶性、低免疫原性和生物相容性聚合物。

生物活性

PEG300 (Polyethylene glycol 300), a neutral polymer of molecular weight 300, is a water-soluble, low immunogenic and biocompatible polymer formed by repeating units of ethylene glycol^[1]^[2].

體外研究(In Vitro)

The FDA has approved polyethylene glycol (PEG) for use as a vehicle or base in foods, cosmetics and pharmaceuticals, including injectable, topical, rectal and nasal formulations. PEG shows little toxicity, and is eliminated from the body intact by either the kidneys (for PEGs < 30 kDa) or in the faeces (for PEGs > 20 kDa). PEG lacks immunogenicity, and antibodies to PEG are generated in rabbits only if PEG is combined with highly immunogenic proteins^[3].

體內(nèi)研究(In Vivo)

Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
The final concentration of PEG300 can go up to 50% in the formulations for intravenous and intramuscular injection without any toxic effects. When administered orally, the highest concentration of PEG300 can reach up to 90%^[4]^[5].

分子量：300.00

性狀：Liquid

CAS 號(hào)：25322-68-3

中文名稱：聚乙二醇

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

4°C, sealed storage, away from moisture

溶解性數(shù)據(jù)

In Vitro:

DMSO : 100 mg/mL (333.33 mM; Need ultrasonic)

H₂O : ≥ 50 mg/mL (166.67 mM)

* "≥" means soluble, but saturation unknown.

參考文獻(xiàn)

[1]. J.Billingham, et al. Adsorption of polyamine, polyacrylic acid and polyethylene glycol on montmorillonite: An in situ study using ATR-FTIR. Volume 14, Issue 1, March 1997, Pages 19-34.
[2]. Lee CC, et al. Structural basis of polyethylene glycol recognition by antibody. J Biomed Sci. 2020 Jan 7;27(1):12.  [Content Brief]
[3]. Harris JM, et al. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003 Mar;2(3):214-21.  [Content Brief]
[4]. Xiaoqin Wang, et al. Injectable silk-polyethylene glycol hydrogels. Acta Biomater. 2015 Jan;12:51-61.  [Content Brief]
[5]. Ellen Weisberg, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.  [Content Brief]
注：產(chǎn)品僅用于科研